Group One Trading
KROS icon

Group One Trading’s Keros Therapeutics KROS Stock Holding History

Group One Trading’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,500
Closed -$295K – 8208
2025
Q4 		$295K Sell
14,500
-400
-3% -$7.02K ﹤0.01% 4026
2025
Q3 		$236K Buy
14,900
+900
+6% +$13.3K ﹤0.01% 4506
2025
Q2 		$187K Sell
14,000
-70,200
-83% -$948K ﹤0.01% 4415
2025
Q1 		$858K Buy
84,200
+81,800
+3,408% +$950K ﹤0.01% 2595
2024
Q4 		$38K Buy
+2,400
New +$125K ﹤0.01% 5263
2024
Q3 		– Sell
-200
Closed -$9.14K – 7002
2024
Q2 		$9.14K Buy
200
+100
+100% +$5.37K ﹤0.01% 5678
2024
Q1 		$6.62K Buy
+100
New +$5.93K ﹤0.01% 6072
2023
Q2 		– Sell
-24,500
Closed -$1.05M – 7945
2023
Q1 		$1.05M Buy
24,500
+7,500
+44% +$379K ﹤0.01% 2100
2022
Q4 		$816K Buy
17,000
+1,900
+13% +$88.8K ﹤0.01% 2602
2022
Q3 		$568K Buy
+15,100
New +$523K ﹤0.01% 3115

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Group One Trading's KROS Position: Q1 2026 in Review

Group One Trading opened a new position in Keros Therapeutics (KROS) in Q1 2026: 734 shares worth $8.1K. The stake represents ﹤0.01% of the portfolio and ranks #6478 among its holdings. This is a return to the name: Group One Trading previously reported a position in KROS as recently as Q3 2025.

Group One Trading first reported a position in KROS in Q2 2022 and has held it in 6 quarters since. The position peaked at $506K in Q1 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Group One Trading held 734 shares of Keros Therapeutics worth $8.1K as of Q1 2026.
  • Keros Therapeutics was a new Group One Trading position in Q1 2026.
  • Keros Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6478 holding.
  • Group One Trading first reported a position in Keros Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • Group One Trading's Keros Therapeutics position peaked at $506K in Q1 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.